ZUG, Switzerland I July 30, 2024 I
Galderma today announced that it has completed its European decentralized procedure (DCP), resulting in a positive decision for Relfydess
TM
(RelabotulinumtoxinA – previously referred to as QM1114). Relfydess
TM
is indicated for the temporary improvement in the appearance of moderate-to-severe glabellar lines (frown lines) at maximum frown and lateral canthal lines (crow’s feet) seen at maximum smile, alone or in combination, in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.
9
Following the successful completion of the DCP, national approvals in the 16 concerned countries are now under finalization. Relfydess
TM
also received a marketing authorization in Australia earlier this year.
Relfydess
TM
is developed and manufactured by Galderma. It is the first and only ready-to-use liquid neuromodulator created with PEARL™ Technology that is designed to preserve molecule integrity to deliver a highly active, innovative, complex-free molecule, with up to 39% of patients seeing effects from day one and up to 75% of patients maintaining improvements for six months for frown lines and crow’s feet.
3,4,7,8
It is optimized for simple volumetric dosing, without reconstitution, to increase ease of use and help ensure consistent dose/volume.
1,10
This positive decision, and the previous Therapeutic Goods Administration approval in Australia, were based on results from the phase III READY (RElabotulinumtoxin Aesthetic Development StudY) clinical trial program, which enrolled more than 1,900 participants. Results showed:
3,4,7,8
Regulatory applications for Relfydess™ for the treatment of frown lines and crow’s feet will continue to be submitted and assessed by additional authorities globally.
About Relfydess
TM
(RelabotulinumtoxinA)
Pioneered by Galderma, Relfydess
TM
is the first and only ready-to-use liquid neuromodulator created with PEARL
TM
Technology that is designed to preserve molecule integrity.
1,2
PEARL
TM
Technology is designed to deliver a highly active, innovative, complex-free molecule, with up to 39% of patients seeing effects from day one and up to 75% of patients maintaining improvements for six months.
1-4,7,8
Relfydess
TM
is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.
1,10
It was entirely developed and manufactured by Galderma to expand its neuromodulator portfolio as part of the broadest Injectable Aesthetics portfolio on the market.
About the READY clinical trial program
The READY (
RE
labotulinumtoxin
A
esthetic
D
evelopment Stud
Y
) phase III clinical program is composed of four phase III clinical trials which enrolled more than 1,900 participants.
3-6
The READY trials investigated the safety, efficacy, rapidity of onset and/or durability of Relfydess
TM
for six months on:
About Galderma
Galderma (SIX: GALD) is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information:
www.galderma.com
.
References:
SOURCE:
Galderma